Evaluation of potential chemical-induced eye injury through irritation and corrosion is required to ensure occupational and consumer safety for industrial, household and cosmetic ingredient chemicals.
Application of Absorption Modeling to Predict Bioequivalence Outcome of Two Batches of Etoricoxib Tablets
As part of the overall product development and manufacturing strategy, pharmaceutical companies routinely change formulation and manufacturing site.
Prediction of blood-brain barrier permeation of a-adrenergic and imidazoline receptor ligands using PAMPA technique and quantitative-structure permeability relationship analysis
Imidazoline receptor ligands are a numerous family of biologically active compounds known to produce central hypotensive effect by interaction with both α2-adrenoreceptors (α2-AR) and imidazoline receptors (IRs).
Interspecies prediction of oral pharmacokinetics of different formulations from dogs to human: physiologically based pharmacokinetic modelling combined with biorelevant dissolution
The aim of the present study was to use physiologically based pharmacokinetic (PBPK) modelling combined with biorelevant dissolution to quantitatively predict dog oral drug pharmacokinetic (PK)...
A Population-Based PK/PD Analysis Of Dasotraline Efficacy In The Treatment Of ADHD In Adults
Dasotraline (SEP-225289) is a new chemical entity with a slow elimination half-life demonstrating dopamine (DAT) and norepinephrine (NET) transporter inhibition in clinical studies. Here we hypothesized…
Evaluation and comparison of benchmark QSAR models to predict a relevant REACH endpoint: The bioconcentration factor (BCF)
The bioconcentration factor (BCF) is an important bioaccumulation hazard assessment metric in many regulatory contexts. Its assessment is required by the REACH regulation...
Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug
In human epilepsy, pharmacoresistance to antiepileptic drug therapy is a major problem affecting a substantial fraction of patients.
Computational Prediction of Drug Solubility in Fasted Simulated and Aspirated Human Intestinal Fluid
To develop predictive models of apparent solubility (Sapp) of lipophilic drugs in fasted state simulated intestinal fluid (FaSSIF) and aspirated human intestinal fluid (HIF).
Simulation of In Vitro Dissolution Behavior Using DDDPlus™
.Dissolution testing is a performance test for many dosage forms including tablets and capsules. The objective of this study was to evaluate if computer simulations can predict the in vitro dissolution of...
Eslicarbazepine Acetate Drug–Drug Interactions: Characterization Through a Model-Based Population Approach
Eslicarbazepine acetate (ESL) is a once-daily (QD) oral antiepileptic drug (AED), approved by the US Food and Drug Administration for the treatment of partial-onset seizures (POS) as monotherapy or...
Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human
Selective kappa opioid receptor antagonism is a promising experimental strategy for the treatment of depression.
Concomitant intake of alcohol may increase the absorption of poorly soluble drugs
Ethanol can increase the solubility of poorly soluble and hence present a higher drug concentration in the gastrointestinal tract.
Rethinking Scientific Workflows
Developing a disease drug model is an intensely creative and collaborative effort. It requires the ability to assemble available knowledge and data and to gain a collective appreciation of important relationships. As this collaborative synthesis gets underway, pharmacometricians are charged with translating the ideas and hypotheses about diseases biology and drug pharmacology into mathematical equations. The equations are then coded into the control streams that, along with the data, become the basis for investigating the feasibility of various hypotheses.
Progressive Reporting and Model Based Drug Development
Over the years, our relationships with clients have deepened and Cognigen is often asked to begin working on projects at the earliest stages of development and to continue to refine a model as new data arrives from ongoing clinical development programs. Consequently, if a assets continues to show promise, we have the opportunity to provide modeling and simulation results at decision-making milestones over the lifecycle of clinical development. Typically, these activities culminate in a comprehensive synthesis of exposure-response relationships for efficacy and safety endpoints that are included in the regulatory submission.
Utilizing Physiologically Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development for a Compound with pH-Dependent Solubility
ARRY-403 is a glucokinase activator developed for the treatment of diabetes. Less than dose-proportional exposure was observed during single ascending dose studies with ARRY-403.
Simulations Plus Reports First Quarter FY2015 Financial Results
Final report of first quarter financial results after Cognigen merger; net revenues up 54%; gross profit increased 41%
Physiologically based pharmacokinetic modelling in drug discovery and development: A pharmaceutical industry perspective
The application of physiologically based pharmacokinetic (PBPK) modeling has developed rapidly within the pharmaceutical industry and is becoming an integral part of drug discovery and development.
Simulations Plus Sets Date for 1st Quarter 2015 Earnings Release and Conference Call
Conference Call to be on Wednesday, January 14, at 4:15 PM ET
Comparison of in silico tools for evaluating rat oral acute toxicity
Different in silico models have been developed and implemented for the evaluation of mammalian acute toxicity, exploring acute oral toxicity data expressed as median lethal dose (LD(50)).